# PACS Group, Inc.: overview

PACS · NYSE · CIK 2001184 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/pacs.md) · [Financials](/companies/pacs/financials.md) · [Filings](/companies/pacs/filings.md) · [Insiders](/companies/pacs/insiders.md)

Latest reported revenue: [$1.43bn](/filings/0002001184-26-000030.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 4, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0002001184-26-000030).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,024](/filings/0002001184-25-000071.md) | [1,208 d](/filings/0002001184-26-000005.md) | [1,277](/filings/0002001184-26-000023.md) | [1,309](/filings/0002001184-26-000030.md) | [1,344](/filings/0002001184-25-000071.md) | [1,358 d](/filings/0002001184-26-000005.md) | [1,420](/filings/0002001184-26-000023.md) | [1,427](/filings/0002001184-26-000030.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [2.2%](/filings/0002001184-25-000071.md) | [6.0% d](/filings/0002001184-26-000005.md) | [3.8%](/filings/0002001184-26-000023.md) | [6.2%](/filings/0002001184-26-000030.md) | [6.4%](/filings/0002001184-25-000071.md) | [7.0% d](/filings/0002001184-26-000005.md) | [8.5%](/filings/0002001184-26-000023.md) | [7.7%](/filings/0002001184-26-000030.md) |
| Net margin | % | [1.5%](/filings/0002001184-25-000071.md) | [3.1% d](/filings/0002001184-26-000005.md) | [2.2%](/filings/0002001184-26-000030.md) | [3.9%](/filings/0002001184-26-000030.md) | [3.9%](/filings/0002001184-25-000071.md) | [4.4% d](/filings/0002001184-26-000005.md) | [5.7%](/filings/0002001184-26-000030.md) | [5.3%](/filings/0002001184-26-000030.md) |
| Diluted EPS | $ per share | [0.10](/filings/0002001184-25-000071.md) | not reported | [0.17](/filings/0002001184-26-000023.md) | [0.31](/filings/0002001184-26-000030.md) | [0.32](/filings/0002001184-25-000071.md) | not reported | [0.50](/filings/0002001184-26-000023.md) | [0.47](/filings/0002001184-26-000030.md) |
| Free cash flow | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY (2022-12-31) | FY (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: |
| Revenue | $m | [2,399](/filings/0002001184-25-000068.md) | [3,110](/filings/0002001184-26-000005.md) | [4,087](/filings/0002001184-26-000005.md) | [5,288](/filings/0002001184-26-000005.md) |
| Gross margin | % | not reported | not reported | not reported | not reported |
| Operating margin | % | [9.6%](/filings/0002001184-25-000068.md) | [6.7%](/filings/0002001184-26-000005.md) | [3.0%](/filings/0002001184-26-000005.md) | [5.9%](/filings/0002001184-26-000005.md) |
| Net margin | % | [6.3%](/filings/0002001184-25-000068.md) | [3.6%](/filings/0002001184-26-000005.md) | [1.4%](/filings/0002001184-26-000005.md) | [3.6%](/filings/0002001184-26-000005.md) |
| Diluted EPS | $ per share | [1.17](/filings/0002001184-25-000068.md) | [0.88](/filings/0002001184-26-000005.md) | [0.38](/filings/0002001184-26-000005.md) | [1.22](/filings/0002001184-26-000005.md) |
| Free cash flow | $m | not reported | not reported | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/pacs/insiders.md)

| Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing |
| --- | --- | --- | --- | ---: | ---: | ---: | --- |
| 2026-10-23 | [Murray Jason Hulse](/insiders/2014386.md) | Co-Founder, CEO & Chairman, Director, Officer, 10% owner | Sale (S) | 46,195 | $48.7885 | $2.3m | [Form 4](/filings/0002014386-26-000024.md) |
| 2026-10-23 | [Murray Jason Hulse](/insiders/2014386.md) | Co-Founder, CEO & Chairman, Director, Officer, 10% owner | Sale (S) | 22,722 | $48.2084 | $1.1m | [Form 4](/filings/0002014386-26-000024.md) |
| 2026-10-22 | [Murray Jason Hulse](/insiders/2014386.md) | Co-Founder, CEO & Chairman, Director, Officer, 10% owner | Sale (S) | 13,696 | $47.5475 | $651.2k | [Form 4](/filings/0002014386-26-000024.md) |

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $264.7m | 6,207,375 |  | Added +959,483 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $177.2m | 4,155,408 |  | Added +380,118 |
| [Crewe Advisors LLC](/funds/1730033.md) | 2026-06-30 | $141.0m | 3,307,188 |  | Added +553,009 |
| [AMERICAN CENTURY COMPANIES INC](/funds/748054.md) | 2026-06-30 | $132.5m | 3,108,196 |  | Added +1,298,565 |
| [AMERIPRISE FINANCIAL INC](/funds/820027.md) | 2026-06-30 | $85.1m | 1,995,116 |  | Added +873,727 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $84.5m | 1,982,621 |  | Added +121,415 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $78.6m | 1,843,496 |  | Added +38,906 |
| [Alyeska Investment Group, L.P.](/funds/1453072.md) | 2026-06-30 | $65.6m | 1,539,065 |  | Reduced −1,463,606 |
| [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $52.5m | 1,230,728 |  | Added +450,569 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $51.5m | 1,208,670 |  | Added +94,927 |

## Recent filings

[All 214 filings](/companies/pacs/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-09-21 | 16:16 ET | [8-K](/filings/0002001184-26-000034.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0002001184-26-000034 |
| 2026-08-04 | 16:03 ET | [8-K](/filings/0002001184-26-000031.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0002001184-26-000031 |
| 2026-08-04 | 16:03 ET | [10-Q](/filings/0002001184-26-000030.md) | Quarterly report, period 2026-06-30 | 0002001184-26-000030 |
| 2026-06-15 | 16:15 ET | [8-K](/filings/0002001184-26-000026.md) | 5.07 Shareholder vote results | 0002001184-26-000026 |
| 2026-05-11 | 16:18 ET | [8-K](/filings/0002001184-26-000024.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0002001184-26-000024 |
| 2026-05-11 | 16:17 ET | [10-Q](/filings/0002001184-26-000023.md) | Quarterly report, period 2026-03-31 | 0002001184-26-000023 |
| 2026-04-28 | 16:30 ET | [DEF 14A](/filings/0002001184-26-000014.md) | Proxy statement, period 2026-06-10 | 0002001184-26-000014 |
| 2026-04-27 | 16:36 ET | [8-K](/filings/0002001184-26-000011.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0002001184-26-000011 |
| 2026-03-05 | 16:32 ET | [8-K](/filings/0002001184-26-000009.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0002001184-26-000009 |
| 2026-02-27 | 21:10 ET | [10-K](/filings/0002001184-26-000005.md) | Annual report, period 2025-12-31 | 0002001184-26-000005 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0002001184-26-000005.md), filed Feb 27, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/6792c743-5b90-49d4-9fbe-5d09655d45c5)

## About the filer

- CIK: 2001184
- Tickers: PACS
- Exchange: NYSE
- SIC code: 8051 Services-Skilled Nursing Care Facilities
- State of incorporation: DE
- Filer category: Accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 19:03 ET. No prices; not investment advice.